Diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: In this two-month course, a double-blind, double-blind, oxidized zinc oxide 100 mg magnesium oxide and 400 mg calcium carbonate in the form of pills containing 200
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Adults (18 years of age and under 65 years of age) People with type 2 diabetes who use the same drug (metformin, glibenclamide, metformin-repaglinide).
Exclusion criteria
Exclusion criteria: Pregnant and lactating people People who are going to have a pregnancy Smoking and alcohol People with polycystic ovary syndrome (if accompanied by type 2 diabetes insulin resistance) Having any underlying heart disease and cancer Species that have kidney, liver and chronic diseases or acute inflammation (especially acute pancreatic inflammation) and thyroid gland diseases Cystic fibrosis (malabsorption) People with gastrointestinal diseases (celiac disease, Crohn's disease, peptic ulcer, diverticulosis, IBD, IBS) People undergoing gastric bypass surgery (malabsorption) People undergoing cholecystectomy (malabsorption) Specimens that were under hormone therapy Insulin injections (due to effect on body weight and insulin levels) Change in the type and dosage of the medications consumed during the intervention Not taking supplements (vitamin D and calcium, etc.) up to three months before the study were treated with drugs and weight loss supplements (such as orlistat or dietary supplements) People who use drugs that cause hyperglycaemia, such as oral or injectable corticosteroids (including prednisone, prednisolone, dexamethasone, triamcinolone, hydrocortisone or betamethasone) People with diabetic foot ulcer Change in the level of physical activity and intense physical activity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum insulin serum level (µIU / ml), 5. 10 ± 1.20 in the placebo group and 7.9 ± 2.7 in the intervention group. Timepoint: Measuring blood insulin at the beginning and end of the study. Method of measurement: Insulin ELISA will be measured. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Cholesterol. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;Triglyceride. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;HDL. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;LDL. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;VLDL. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;Physical activity. Timepoint: Before and after intervention. Method of measurement: questionnaire MET.;Systolic blood pressure. Timepoint: Before and after intervention. Method of measurement: Mercury pressure gauge.;Diastolic blood pressure. Timepoint: Before and after intervention. Method of measurement: Mercury pressure gauge.;BMI. Timepoint: Before and after intervention. Method of measurement: With the Inbody 770 Analyzer.;Body composition. Timepoint: Before and after intervention. Method of measurement: With the Inbody 770 Analyzer.;Fasting blood sugar. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;HbA1C. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;CRP. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;ALT. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;AST. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;GGT. Timepoint: Before and after intervention. Method of measurement: Dialab Kit Original Ultraviolet Auto analyzer BT-1500.;ALP. Timepoint: Before and after inter | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMostafa badeli
Oroumia University of Medical Sciences
Outcome results
None listed